Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021216615 - HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION

Publication Number WO/2021/216615
Publication Date 28.10.2021
International Application No. PCT/US2021/028245
International Filing Date 20.04.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
G16B 15/20 2019.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
15ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
20Protein or domain folding
CPC
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 2039/572
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
57characterised by the type of response, e.g. Th1, Th2
572cytotoxic response
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12N 2770/20034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
G16B 15/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
15ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
20Protein or domain folding
Applicants
  • THE GENERAL HOSPITAL CORPORATION [US]/[US]
  • MASSACHUSETTS EYE AND EAR INFIRMARY [US]/[US]
Inventors
  • GAIHA, Gaurav
  • ROSSIN, Elizabeth, Jeffries
Agents
  • DECAMP, James, D.
  • TITTEL, Jan, N.
Priority Data
63/012,56520.04.2020US
63/019,29302.05.2020US
63/125,11414.12.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION
(FR) COMPOSITION IMMUNOGÈNE DE CORONAVIRUS À ÉPITOPES AYANT UN SCORE DE RÉSEAU ÉLEVÉ
Abstract
(EN) A method of preventing or treating COVID infection in a subject includes selecting two or more COVED CTL epitopes from a Coronavirus proteome that have a network score that meets a threshold value. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected Coronavirus CTL epitopes.
(FR) L'invention concerne un procédé de prévention ou de traitement de l'infection par la COVID chez un sujet qui comprend la sélection d'au moins deux épitopes CTL COVID de provenant d'un protéome de Coronavirus qui ont un score de réseau qui atteint une valeur seuil. Une quantité efficace d'une composition immunogène de lymphocyte T et d'un support pharmaceutiquement acceptable est administrée au sujet. La composition immunogène de lymphocytes T comprend les deux ou plus de deux épitopes CTL de coronavirus sélectionnés.
Latest bibliographic data on file with the International Bureau